Fear over NICE guidance on prostate cancer drug

January 28, 2014 2:19 pm

It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence.  Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.

The pharmaletter.

January 28, 2014 2:19 pm


Sign up to receive analysis on policy developments across our specialist sectors

Contact us

For more information about how Whitehouse can help you, please contact:

Viviana Spaghetti
t: +44 (0)20 3855 5760
m: +44 (0)7583 051119

For media enquiries, please contact:
Mayar Raouf

t: +44 (0)20 3855 5760
m: +44 (0)7502 327092

For career and jobs information, please contact:
t: +44 (0)20 3855 5760

For general enquiries, please contact:
t: +44 (0)20 3855 5760

Sign up for the latest news

  • * Denotes required fields
  • This field is for validation purposes and should be left unchanged.